← GLP-1 receptor agonists × glycemic control

Observational studyFrontiers in endocrinology2022

Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain.

Maria Dolores Garcia de Lucas et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 166 people · 2022

No range given

Reported lower glycemic control, no range given

−0.70percentage points

As reported

difference −0.70 %, no interval

One number in the abstract

the abstract, start to end

… the reductions in HbA1c were -0.91 ± 0.7% (p<0.001) in the total cohort, …

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Glycemic control
−0.70
GLP-1 receptor agonistsGlycemic control
1 / 3

9 papers cite it

2022
2023
2024
2025
2026
this papercites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 36187123